Benitec Biopharma (BNTC) Receivables (2019 - 2025)
Benitec Biopharma's Receivables history spans 7 years, with the latest figure at $3000.0 for Q1 2025.
- For Q1 2025, Receivables fell 94.34% year-over-year to $3000.0; the TTM value through Mar 2025 reached $3000.0, down 94.34%, while the annual FY2024 figure was $229000.0, 316.36% up from the prior year.
- Receivables for Q1 2025 was $3000.0 at Benitec Biopharma, up from $2000.0 in the prior quarter.
- Across five years, Receivables topped out at $229000.0 in Q2 2024 and bottomed at $2000.0 in Q4 2024.
- The 5-year median for Receivables is $10000.0 (2021), against an average of $37058.8.
- The largest annual shift saw Receivables soared 1733.33% in 2023 before it crashed 96.23% in 2024.
- A 5-year view of Receivables shows it stood at $5000.0 in 2021, then skyrocketed by 1260.0% to $68000.0 in 2022, then decreased by 22.06% to $53000.0 in 2023, then plummeted by 96.23% to $2000.0 in 2024, then soared by 50.0% to $3000.0 in 2025.
- Per Business Quant, the three most recent readings for BNTC's Receivables are $3000.0 (Q1 2025), $2000.0 (Q4 2024), and $4000.0 (Q3 2024).